Author of the publication

Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia

, , , , , , , , , , , , and . Blood, 117 (10): 2918–2923 (2011)

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Hyperphosphorylated paratarg-7: a new molecularly defined risk factor for monoclonal gammopathy of undetermined significance of the IgM type and Waldenstrom macroglobulinemia, , , , , , , , , and 3 other author(s). Blood, 117 (10): 2918–2923 (2011)KMWin--a convenient tool for graphical presentation of results from Kaplan-Meier survival time analysis, , and . PloS one, 7 (6): e38960 (2012)Circulating levels of TNF receptor II are prognostic for patients with peripheral T-cell non-Hodgkin lymphoma, , , , , , , , , and 1 other author(s). Clinical cancer research : an official journal of the American Association for Cancer Research, 18 (13): 3637–3647 (2012)Histopathological diagnosis of graft-versus-host disease of the skin--an interobserver comparison, , , , , , , and . Journal of the European Academy of Dermatology and Venereology : JEADV, 28 (7): 915–924 (2014)CHO(E)P-14 followed by alemtuzumab consolidation in untreated peripheral T cell lymphomas: final analysis of a prospective phase II trial, , , , , , , , , and . Annals of hematology, 92 (11): 1521–1528 (2013)High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma, , , , , , , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 21 (11): 2255–2261 (2010)High-dose CHOP plus etoposide (MegaCHOEP) in T-cell lymphoma: a comparative analysis of patients treated within trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL), , , , , , , , and . Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 20 (12): 1977–1984 (2009)Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone), , , , , , , , , and 2 other author(s). Annals of hematology, 87 (9): 717–726 (2008)MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma, , , , , , , , , and 10 other author(s). Blood, 121 (12): 2253–2263 (2013)Loss of HLA-DR expression and immunoblastic morphology predict adverse outcome in diffuse large B-cell lymphoma - analyses of cases from two prospective randomized clinical trials, , , , , , , , , and 10 other author(s). Haematologica, 94 (11): 1569–1580 (2009)